Apnimed
Developer of a pharmacologic therapy designed to target orally dosed medicines, the key underlying neurobiological mechanisms that lead to airway obstruction. The company's therapeutics address the ph...
Valuation
$440M
Market implied
Share Price
N/A
Total Raised
$259.3M
Last Round
N/A